About Anu Bio

This company develops novel immunotherapies and antibody-based drugs using proprietary AI architecture for drug discovery. Their foundational AI model creates a digital twin of the human immune system to drive data-driven decisions across development stages. This platform enables the discovery and de-risking of promising drug candidates, particularly against cancer.

```xml <problem> The development of effective immunotherapies for cancer is hindered by the complexity of immune system interactions and the difficulty in predicting clinical performance of drug candidates. Traditional drug discovery methods often struggle to translate findings from animal models to human trials, leading to high failure rates and increased development costs. </problem> <solution> AnuBio is developing a closed-loop, lab-AI drug discovery platform to accelerate the development of immunotherapies and antibody-based drugs, specifically for lung and skin cancer. The company's core technology combines a proprietary wet-lab platform, PHENOMS (Phenotypic Screening + Multispecific Biologics), with the TRAILBLAZER AI framework. This integrated system explores and manipulates immune signaling networks to enhance the predictability of human clinical performance for lead candidates. By integrating real-world data from PHENOMS with AI-driven predictions from TRAILBLAZER, AnuBio aims to rationalize target and drug selection at every stage of the discovery process, derisking drug development. </solution> <features> - PHENOMS: A high-throughput, combinatorial, phenotypic discovery platform for biologics, enabling exhaustive screening of cellular signaling. - TRAILBLAZER AI: A foundational AI model of the immune system that predicts drug discovery success by integrating cellular response data, drug developability characteristics, and clinical trial modeling. - Molecular modeling of animal and human immune system perturbations with single-cell resolution. - Drug developability modeling to assess the feasibility and manufacturability of drug candidates. - Clinical trial modeling to simulate and predict the outcomes of clinical trials. - A proprietary library of biologically relevant perturbations of the immune system for training the TRAILBLAZER AI model. </features> <target_audience> AnuBio's primary customers are pharmaceutical companies and research institutions focused on developing novel immunotherapies for cancer. </target_audience> ```

What does Anu Bio do?

Where is Anu Bio located?

Anu Bio is based in San Leandro, United States.

When was Anu Bio founded?

Anu Bio was founded in 2024.

Location

San Leandro, United States

Founded

2024

Employees

4 employees

Anu Bio

San Leandro, United StatesFounded 20244100+ followers4/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

The development of effective immunotherapies for cancer is hindered by the complexity of immune system interactions and the difficulty in predicting clinical performance of drug candidates. Traditional drug discovery methods often struggle to translate findings from animal models to human trials, leading to high failure rates and increased development costs.

Solution

AnuBio is developing a closed-loop, lab-AI drug discovery platform to accelerate the development of immunotherapies and antibody-based drugs, specifically for lung and skin cancer. The company's core technology combines a proprietary wet-lab platform, PHENOMS (Phenotypic Screening + Multispecific Biologics), with the TRAILBLAZER AI framework. This integrated system explores and manipulates immune signaling networks to enhance the predictability of human clinical performance for lead candidates. By integrating real-world data from PHENOMS with AI-driven predictions from TRAILBLAZER, AnuBio aims to rationalize target and drug selection at every stage of the discovery process, derisking drug development.

Target Audience

AnuBio's primary customers are pharmaceutical companies and research institutions focused on developing novel immunotherapies for cancer.

Features

PHENOMS: A high-throughput, combinatorial, phenotypic discovery platform for biologics, enabling exhaustive screening of cellular signaling.
TRAILBLAZER AI: A foundational AI model of the immune system that predicts drug discovery success by integrating cellular response data, drug developability characteristics, and clinical trial modeling.
Molecular modeling of animal and human immune system perturbations with single-cell resolution.
Drug developability modeling to assess the feasibility and manufacturability of drug candidates.
Clinical trial modeling to simulate and predict the outcomes of clinical trials.
A proprietary library of biologically relevant perturbations of the immune system for training the TRAILBLAZER AI model.